Genmab: Janssen applies for approval for lung cancer drug in the US

Genmab's collaborative partner Janssen has submitted a Biologics License Application to the FDA for the lung cancer treatment amivantamab, which was developed from the basis on Genmab's Duobody technology.

Photo: PR / Genmab

The license approval application to the US Food and Drug Administration concerns patients with metastatic non-small cell lung cancer (NSCLC) with a particular set of mutations. Furthermore, patients need to have had relapses after being treated with chemotherapy, according to an announcement from Genmab.

If the drug is approved, Genmab will get a portion of Janssen's future sales.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs